# NAD+ Benefits and Aging in the Research Literature

> NAD+ benefits in the aging literature: tissue NAD+ falls with age as CD38 rises, and precursors restore blood NAD+ — but the 2025 Nature Metabolism review calls human efficacy preliminary.

Tissue NAD+ falls with age, and rodent data on restoring it are striking. The human chapter is where the claims get careful.

## In plain English

This page is about the most-searched claim on the topic: the **NAD+ benefits** people hope for as they age. Here is the honest shape of it. NAD+ (the energy-handling coenzyme every cell uses) drops in your tissues as you get older, partly because an enzyme called CD38 (which clears NAD+) climbs with age. In mice, blocking that decline does impressive things — better mitochondria, healthier metabolism. In people, supplements made from NAD+ precursors clearly raise the NAD+ in your blood, but the big payoffs — living longer, preventing disease, looking younger — have not been proven yet. Strong biology, promising rodent data, preliminary human results.

## Why NAD+ declines with age

The decline itself is one of the better-established facts in the field. Across model organisms and humans, tissue NAD+ falls with age, and the foundational reviews link that fall to metabolic dysfunction and disease susceptibility by mapping the enzymes that compete for the NAD+ pool — sirtuins (SIRT1-7), PARPs (chiefly PARP1), and CD38/CD157 [5]. The clearest single driver is CD38: this NAD-consuming ectoenzyme rises with age and inflammation, and in mice its deletion preserves NAD+ levels and SIRT3 activity, improving mitochondrial function and metabolic health into old age [2]. Senescent cells contribute too, secreting inflammatory factors that activate CD38-positive macrophages and accelerate the local NAD+ drain [5]. Restoring NAD+ — with precursors fed into the salvage pathway through the rate-limiting enzyme NAMPT [6] — is the candidate strategy that follows from this biology.

## What the anti-aging research actually shows in animals vs humans

In rodents, NAD+ restoration produces broad effects. A 2024 critical review of NMN's anti-aging mechanisms identifies four core pathways — cellular energy metabolism, apoptosis inhibition, immune modulation, and genomic-stability preservation — and documents NMN activating sirtuins, lowering CD38 and PARP-1 activity, and promoting anti-inflammatory M2 macrophages [12]. A systematic review of preclinical cognitive-disease models found repeated parenteral NAD+ precursor dosing over 7-28 days most effective, while a single subcutaneous NMN injection (1.2 g/kg) did nothing — route and duration matter [15].

The human chapter is more guarded. Precursor trials reliably raise blood NAD+ [4][3], and one reported improved muscle insulin sensitivity [1], but the 2025 Nature Metabolism review concluded human trials have shown limited efficacy on hard endpoints, that age-related NAD+ decline has been confirmed in only a limited number of human studies, and that tissue-specific NAD+ data remain sparse — a call for more clinical work, not a green light from rodent extrapolation [10]. Much of the strongest anti-aging signal still comes from mice and may not carry over [10].

## What NAD+ benefits have not been demonstrated

It is worth stating the gaps plainly, because they are where the marketing outruns the data. No cited study measured a cosmetic 'younger appearance' in people — that claim has no controlled human endpoint behind it [10]. NAD+ precursors have not been shown to extend human lifespan or prevent age-related disease [10]. The metabolic story is mixed: a single 250 mg/day NMN trial improved muscle insulin sensitivity [1], but a 12-trial meta-analysis found no significant effect on glucose or lipids [14]. And one caution belongs here: NAD+ supports proliferating cells, so a theoretical concern exists that raising it could fuel existing cancers — its role in oncology is dual and context-dependent, warranting caution in cancer populations [10]. The biology behind the hoped-for NAD+ benefits is compelling; the human benefit ledger is, for now, mostly open.

---

A billboard reading of the NAD+ record — the precursor trials that reliably raise blood NAD+ set in large type, the rapidly-cleared IV claims and the still-preliminary human endpoints qualified in the line beneath, the FDA injectable recall and the NMN-supplement dispute flagged in plain sight; no clinic behind the broadcast and nothing here infused, dosed, prescribed, or sold.